2022
Selected as one of the "2022 Top 100 Chinese Pharmaceutical Innovative Enterprises"
2022
Included in the list of 2022’s Most Innovative Companies on the STAR Market
2021
Selected as one of the "Top 30 Chinese Innovative Enterprises in Small Molecule Drug"
2020
Selected as one of the "Top 100 Chinese Enterprises in Medical Innovation"
2020
Selected as one of the "Top 80 China's Healthcare Innovation Enterprises"
2020
Selected as one of the "Hurun China Cheetahs 2020"
2020
Selected as one of the "2020 Chinese Venture Company in High Growth"
2020
Awarded the "Research and Development Frontier Award"
2020
Selected as one of the "Small to Mid-sized Scientific and Technological Enterprises" of China
2019
Cevira® 2019 Fierce Innovation Awards – Life Sciences Edition in the category of Medical Device Innovation.
2019
Dr. Yijun Deng, Vice President of Drug Discovery of Asieris was selected into "113 Medical Talents Program" of CMC
2019
Selected as one of the "Small to Mid-sized Scientific and Technological Enterprises" of China
2018
Selected as one of the "Small to Mid-sized Scientific and Technological Enterprises" of China
2018
APL-1501 awarded as recipient of the "National 13th Five-Year Major New Drug Innovation Program"
2017
Selected as one of the "Small to Mid-sized Scientific and Technological Enterprises" of China
2017
APL-1202 awarded as one of the "National 13th Five-Year Major New Drug Innovation Programs"
2015
Selected as one of the “Small to Mid-sized Scientific and Technological Enterprises” in Jiangsu Province.
2015
Asieris' APL-1202 awarded as recipient of the "National 12th Five-Year Major New Drug Innovation Program";
2012
Awarded an "International Technology Transfer and Joint R&D Project" grant and a "Science and Technology Driven Social Development Projects" funding support by the Science and Technology Department of Jiangsu Province.
